Flaviviridae Infections is an indication for drug development with over 350 pipeline drugs currently active. According to GlobalData, preregistered drugs for Flaviviridae Infections have a 78.95% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Flaviviridae Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Flaviviridae Infections overview
Fiavivirideae infections are caused by a family of enveloped RNA viruses that mainly infect mammals and birds. They are transmitted by arthropod vectors, such as mosquitoes and ticks. Some of the diseases caused by this family include yellow fever, dengue fever, hepatitis C, Japanese encephalitis, and Zika virus. These diseases can range from mild to severe, and can cause hemorrhagic fever, neurological disorders, or birth defects. Fiavivirideae infections are a global public health concern, especially in tropical and subtropical regions where the vectors are prevalent. Prevention and control measures include vector surveillance, vaccination, and antiviral therapy.
For a complete picture of PTSR and LoA scores for drugs in Flaviviridae Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
